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eAppendix: Technical Appendix
Herein we detail (1) the definitions of patient risk groups, (2) the distributions of high-, medium-, and lowvolume hospitals, (3) the derivation of direct health care costs, (4) the distributions used in probabilistic sensitivity analyses, and (5) additional sensitivity analyses.
Definition of Risk Groups
The original risk categories were derived from previous work with Medicare claims data 1 based on 3 factors: age (Ͻ70 years, 70-80 years, or Ͼ80 years); Charlson comorbidity index 2 (no comorbidities, 1-2 comorbidities, or Ͼ2 comorbidities); and poverty status (Medicaid eligibility). Each of those variables was assigned a value of 0, 1, or 2 (only 0 or 1 for poverty indicator), and a summary score was determined: 0, low risk (age, Ͻ70 years; Charlson comorbidity index, 0; and ineligible for Medicaid); 1 to 2, medium risk; and higher than 2, high risk. These risk stratifications were validated by association with perioperative complications and functional outcomes 2 years postoperatively. Patients undergoing total knee arthroplasty (TKA) with lower risk scores had lower rates of perioperative complications and better functional status 2 years after TKA. Therefore, the outcomes data used in the current analysis were derived from these risk categories.
The quality of life data and cost data were derived from different data sources. While we attempted to maintain similar definitions of risk groups, poverty status, defined by Medicaid eligibility, was not available in either the Kinemax study 3 used for quality of life estimates or in the Third National Health and Nutritional Examination Survey (NHANES III) data. 4 Therefore, we used age and comorbidities to create risk groups for cost and quality of life analysis.
2. Distribution of High-, Medium-, and LowVolume Hospitals and Patients eTable 1 summarizes the distribution of hospital volume derived from a previous study. 
Derivation of Direct Health Care Costs
Direct medical costs of end-stage knee osteoarthritis (OA) management, TKA, revision TKA, and complications associated with surgical OA treatment were derived from multiple sources and based on 2006 US dollars. Charges (2005 US dollars) for complications were obtained from the Health Care Utilization Project for Medicare beneficiaries. 5 We considered 4 complications, including joint infection (International Classification of Diseases, Ninth Revision [ICD-9] code 996.66), pneumonia (Clinical Classification Software [CCS] code 122), myocardial infarction (CCS code 100), and pulmonary embolism (ICD-9 code 415.11). These charges were converted to 2006 US dollars using consumer price index data from the Bureau of Labor Statistics. 6 Next, the charges were converted to costs using a cost-charges ratio of 0.6 (unpublished data). The prevalence of each complication was extracted from Medicare claims data. 1 To find the overall cost of these complications, we multiplied each complication's cost in 2006 US dollars by each complication's weighted prevalence and summed the values to find the population's average cost of $12 600. The derivation of direct medical costs related to living with end-stage knee OA, TKA revision, and TKA are detailed in eTable 2, 4,7-10 eTable 3, [11] [12] [13] and eTable 4. 1 We assumed that patients who had a successful TKA would experience a reduction in costs after surgery. Specifically, we assumed that patients with a successful TKA would have 2 fewer physician visits per year (2ϫ$54), an annual reduction in radiography costs of 50% (0.5ϫ$23), and no annual costs from OA medications ($392) (eTable 2). As a result, health care costs for patients with a successful TKA would be reduced by $512. 9 we estimated that 20.6% of patients who saw physicians received an MRI or radiogram. We also assumed that patients who did not see physicians (13%) did not incur imaging costs and adjusted the average annual imaging costs accordingly. For example, the average annual imaging costs for a low-risk patient was calculated by multiplying $276 ϫ 0.206ϫ (1 − 0.130) for a final value of $49. We used a similar approach for the other risk groups.
e The total annual costs for patients in each risk group were calculated as the sum of inpatient, outpatient, imaging, and pharmacy annual costs. The overall annual cost was calculated as the weighted average of costs for patients in each risk group. Abbreviations: CPT, Current Procedural Terminology; DRG, Diagnosis-Related Group; IRF, inpatient rehabilitation facility; SNF, skilled nursing facility; TKA, total knee arthroplasty.
a The 2006 US dollar CPT costs for primary and revision TKAs were obtained from the Physician Fee Schedule available through the Medicare Web site. 11 We searched for pricing information for CPT codes 27447 (primary TKA) and 27487 (revision TKA) for all national carriers with global modifier codes.
b The 2006 US dollar DRG costs for primary (544) and revision (545) TKAs were also obtained from the Medicare Web site. 12 We divided total Medicare reimbursement costs (2006 US dollars) for each code by the total number of applicable discharges in 2006.
c We obtained per-patient "inpatient" and "at home" costs from published literature. 13 Inpatient postsurgical care costs were derived from both IRF and SNF costs. Values provided were given in 2002 US dollars, which we inflated to 2006 US dollars. Based on the data from the national sample of Medicare beneficiaries undergoing TKA, of those who went to rehabilitation centers, approximately 50% went to IRFs and 50% went to SNFs. We averaged SNF and IRF costs to estimate mean inpatient rehabilitation costs. Costs of primary and revision TKA stratified by patient risk and hospital volume were derived by first multiplying the proportion of each cohort that was discharged to SNF and IRF by the cost of inpatient treatment (from eTable 3). Next we multiplied the proportion of the cohort that did not have inpatient treatment by the cost of at-home treatment (from eTable 3) to find the cost of at-home treatment for a given cohort. Finally we added these 2 products to the DRG and CPT costs for either primary or revision TKA to the appropriate DRG and CPT costs from eTable 3, yielding either primary or revision TKA costs. 
Distributions Used in Probabilistic Sensitivity
Analyses eTable 5 summarizes the distributions used in probabilistic sensitivity analyses for low-and high-risk patient groups.
Additional Sensitivity Analyses
We conducted 3 additional sensitivity analyses: (1) eFigure 1. Two-way sensitivity analysis of the impact of revision rates and functional improvement after revision. Total knee arthroplasty (TKA) remains highly cost-effective in the overall US population, even if revisions lead to a very low proportion of individuals who reach satisfactory functional status. For example, even if revision TKA leads to satisfactory functional improvement in only 10% of cases, the cost-effectiveness ratios for TKA range from $19 700 to $78 500 assuming 1-to 10-fold increases, respectively, in revision TKA rates relative to the baseline rate (0.0067 revision per year). QALY indicates quality-adjusted life year. Two-way sensitivity analysis of the impact of quality of life (QOL) before total knee arthroplasty (TKA) on amount of post-TKA improvement and the impact of pre-TKA and post-TKA QOL on the cost-effectiveness of TKA. We considered percentage improvement in QOL for TKA leading to satisfactory improvement in functional status ranging from 115% to 125% of pre-TKA QOL, with the base case value being 121%. We also examined ranges in preoperative QOL varying from 25% reduction to 20% increase (25% reduction in QOL index of 0.690 resulted in utility index of 0.518). As a reference point, the utility index of stable metastatic breast cancer has been reported as 0.715; progressive metastatic breast cancer, 0.443. 14 Cost-effectiveness of TKA remains below $50 000 per quality-adjusted life year (QALY) for all considered scenarios if post-TKA QOL improvement is at least 15%. For example, in the worst-case scenario considered, in which pre-TKA QOL is reduced to 75% of the baseline value (0.518) and TKA yields only a 15% QOL improvement (to 0.596), the cost-effectiveness of TKA is still below $50 000. (All dollar amounts are reported in 2006 US dollars.) 
